Center for drug evaluation, NMPA held an expert seminar on hot issues of children's medicine research and development

In order to implement the important instructions of General Secretary Xi Jinping on children's medicine, carry out the practical activities of "I do practical things for the public", and make efforts to solve the shortage of children's medicine, the Center held an expert seminar on the hot issues of children's medicine R&D on September 24, inviting pediatric clinical research institutions, domestic and foreign enterprises dedicated to children's medicine R&D to discuss the application of "joint working mode" in children's medicine industry and seek common development. Comrade Kong Fanpu, Director of the Center, attended the meeting and made a speech.

Kong Fanpu pointed out that, after the previous stage of exploration and practice, the implementation of the joint work model of production, academia, research and review around children's medicine has taken shape, and several links have been achieved or are being promoted. For example, three special guidelines for children's medicine has been released this year by the research and development enterprises, research units and regulatory agencies working together to complete, through the integration of resources, close communication, to ensure that the guidelines are both scientific and feasible, to lay a good foundation for the subsequent implementation. Kong Fanpu stressed that enterprises are the main body of medicine R&D, and are the core force to solve the problem of shortage of medicine for children in China. Pediatric clinical research institutions are not only the users and promoters of medicine, but also play an important role in comprehensively assessing the clinical value and quality of medicine. Therefore, only through the cooperation of industry, academia, research and audit, and through concentrated efforts for development, can we create a good industrial ecology and achieve a win-win collaboration, which will eventually provide a solid foundation and a strong boost for the rise of China's pediatric medicine industry.

In the discussion session, the participants exchanged their views on the problems and strategies in the R&D of pediatric medicine in China. Ni Xin, President of the National Children's Medical Center (Beijing Children's Hospital), made a speech on behalf of pediatric clinical research institutions, and representatives from the China Association of Foreign Invested Enterprises Pharmaceutical Development and Development Industry Committee (RDPAC), China Pharmaceutical Innovation Promotion Association (CPIPA) and China Pharmaceutical News and Information Association (CPIA) Children's Safe Drug Use Branch sent representatives to elaborate their opinions and suggestions.

This meeting is a stage summary meeting of RDPAC to implement the important decision and deployment of the Party Central Committee and take multiple measures to promote the R&D and innovation of children's medicine, and will also serve as a new starting point for the next stage of RDPAC's work on children's medicine, to promote the orderly development and continuous innovation of China's children's medicine industry by further establishing a mechanism of extensive cooperation and linkage among industry, academia, research and review, to efficiently solve the shortage of children's medicine. It will efficiently solve the problem of children's medicine shortage and promote the healthy development of children's body and mind.

The members of the special working group for children's medicine use of the Drug Review Center attended the meeting.